Using End-Tidal CO₂ to Help Diagnose and Monitor Pulmonary Embolism
Key facts
- Who runs it
- Ataturk University
- Where
- Türkiye1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 120 people enrolled
- Started
- 1 Feb 2025
- Ended
- 30 Jul 2025
- Type of study
- Observational, 4 groups
- Treatments tested
- thrombolytic therapy
- Record updated
- 22 December 2025
Who can take part
- Age
- 18 years to 80 years
- Sex
- Women and men
The registry criteria, word for word
Show all 2 criteriaShow less
Who can take part
- Adults aged 18 years or older Diagnosis of acute pulmonary embolism confirmed by CT pulmonary angiography (for PE groups) Classified as high-risk or intermediate-high-risk pulmonary embolism according to ESC/ERS 2019 guidelines Ability to provide informed consent For healthy control group: no history of cardiopulmonary disease, coagulation disorders, or acute medical illness
Who cannot take part
- Known chronic respiratory diseases significantly affecting EtCO₂ measurement (e.g., advanced COPD, severe asthma, chronic respiratory failure) Active infection, sepsis, or acute complications of malignancy Prior thrombolytic therapy for pulmonary embolism Anatomical or technical limitations preventing reliable nasal capnography Pregnancy Individuals younger than 18 years Inability or refusal to provide informed consent
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Pulmonary embolism (PE) can reduce blood flow in the lungs and impair gas exchange, leading to lower end-tidal carbon dioxide (EtCO₂) levels. This prospective observational study aims to evaluate whether EtCO₂ can help identify high-risk and intermediate-high-risk patients and monitor early treatment response, especially during thrombolytic therapy. A total of 120 participants were included: high-risk PE, intermediate-high-risk PE patients who received thrombolysis, intermediate-high-risk PE patients treated only with anticoagulation, and healthy controls.
Read full original descriptionShow less
The study measured EtCO₂ along with oxygen saturation, heart rate, respiratory rate, perfusion index, and radiological obstruction scores. By comparing these parameters at diagnosis and during the first 24 hours, the study seeks to determine whether EtCO₂ can serve as a simple, noninvasive marker of disease severity and early hemodynamic improvement in patients with acute PE.
The 4 groups in the trial
- Group 1: High-Risk Pulmonary Embolism (Thrombolysis)
Patients presenting with shock or persistent hypotension and receiving systemic thrombolytic therapy.
Treatment: thrombolytic therapy
- Group 2: Intermediate-High-Risk Pulmonary Embolism (Thrombolysis)
Hemodynamically stable patients with RV dysfunction and elevated biomarkers who required thrombolysis.
Treatment: thrombolytic therapy
- Group 3: Intermediate-High-Risk Pulmonary Embolism (Non-Thrombolysis)
Patients meeting intermediate-high-risk criteria but treated with anticoagulation only.
- Group 4: Healthy Controls
Individuals without cardiopulmonary disease and with normal clinical and laboratory findings.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Assessment of End-Tidal CO₂ Levels in the Diagnosis and Management of Patients With Pulmonary Embolism
- Publications
- Assessment of end-tidal CO₂ levels in the diagnosis and management of patients with pulmonary embolism.BMC pulmonary medicine, 2026
- Record updated
- 22 December 2025